Company intelligence / Profile preview

SereNeuro Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

SereNeuro Therapeutics has not yet reported clinical results. The company’s lead program, SN101 iPS cell therapy, aims to provide non-opioid relief for chronic knee osteoarthritis by reducing pain and regenerating bone density. No published data on human trials as of February/March 2025.

Therapeutic areas: Rheumatology
Modalities: Cell therapy (iPS cell therapy)Gene therapy
Industry: Biotech

Drug pipeline

2 assets

SN101

Preclinical

1 more asset in the full pipeline.

Beyond the preview

Go deeper on SereNeuro Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SereNeuro Therapeutics.